Molekul oštećenja bubrega-1 (KIM-1) i akvaporin-1 (AQP-1) u urinu kod bolesnika sa karcinomom svetlih ćelija bubrega: potencijalni neiznvazivni biomarkeri

  • Mirjana M Mijušković Vojnomedinska akademija
  • Ivan Stanojević Institute for Medical Research, Military Medical Academy, Belgrade, Serbia
  • Novak Milović Clinic of Urology, Military Medical Academy, Belgrade, Serbia; Faculty of Medicine of the Military Medical Academy, University of Defence, Belgrade, Serbia
  • Snežana Cerović Institute of Pathology, Military Medical Academy, Belgrade, Serbia; Faculty of Medicine of the Military Medical Academy, University of Defence, Belgrade, Serbia
  • Dejan Petrović Clinic of Urology, Nephrology and Dialysis, Clinical Center of Kragujevac, Faculty of Medical Sciences, University of Kragujevac, Serbia
  • Dragan Jovanović Clinic of Nephrology, Military Medical Academy, Belgrade, Serbia; Faculty of Medicine of the Military Medical Academy, University of Defence, Belgrade, Serbia
  • Predrag Aleksić Clinic of Urology, Military Medical Academy, Belgrade, Serbia; Faculty of Medicine of the Military Medical Academy, University of Defence, Belgrade, Serbia
  • Božidar Kovačević Institute of Pathology, Military Medical Academy, Belgrade, Serbia
  • Tamara Andjelić Institute of Medical Biochemistry, Military Medical Academy, Belgrade, Serbia
  • Brankica Terzić Clinic of Nephrology, Military Medical Academy, Belgrade, Serbia
  • Mirjana Djukić Department of Toxicology, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia
  • Danilo Vojvodić Institute of Medical Biochemistry, Military Medical Academy, Belgrade, Serbia; Faculty of Medicine of the Military Medical Academy, University of Defence, Belgrade, Serbia of the Military Medical Academy, University of Defence, Belgrade, Serbia
DOI: https://doi.org/10.2298/7608
Ključne reči: kidney neoplasms||, ||bubreg, neoplazme, diagnosis||, ||dijagnoza, biological markers||, ||biološki pokazatelji, urine||, ||mokraća, nephrectomy||, ||nefrektomija,

Sažetak


Uvod/Cilj. Molekul oštećenja bubrega-1 (KIM-1) i akvaporin-1 (AQP-1) su potencijalni rani biomarkeri karcinoma svetlih ćelija (cRCC). Cilj ove studije bio je da se utvrdi povezanost između koncentracija KIM-1 i AQP-1 u urinu i veličine, gradusa, stadijuma i vrste operacije (radikalna ili parcijalna nefrektomija) kod bolesnika sa cRCC. Metode. Urinarne koncentracije KIM-1 i AQP-1 određene su primenom komercijalnih ELISA kitova. Analizom je bilo obuhvaćeno 40 bolesnika koji su bili podvrgnuti parcijalnoj ili radikalnoj nefrektomiji zbog tumora bubrega i 40 zdravih odraslih ispitanika. Grupe su bile komparabilne po polu i godinama života. Rezultati. Srednja preoperativna koncentracija urinarnog KIM-1 (uKIM-1) u cRCC grupi [0,724 ± 1,120 ng/mg kreatinia u urinu (Ucr)] bila je statistički značajno viša u poređenju sa koncentracijom u kontrolnoj grupi (0,210 ± 0,082 ng/mgUcr ) (p = 0,0227). Postoperativno, koncentracija uKIM-1 značajno je padala i približavala se vrednosti u kontrolnoj grupi (0,177 ± 0,099 ng/mgUcr nasuprot 0,210 ± 0,082 ng/mgUcr). Veličina, gradus i stadijum tumora bili su u pozitivnoj korelaciji sa preoperativnim koncentracijama uKIM-1. Nasuprot ovim rezultatima, koncentracija urinarnog AQP-1 (uAQP-1) u cRCC grupi bila je značajno niža (0,111 ± 0,092 ng/mgUcr) u poređenju sa kontrolnom grupom zdravih osoba (0,202 ± 0,078 ng/mgUcr) (p = 0,0014). Postoperativno, koncentracija uAQP-1 progresivno se povećavala, približno do vrednosti u kontrolnoj grupi. Nismo našli značajnu korelaciju između preoperativnih koncentracija uAQP-1 i veličine, gradusa i stadijuma tumora. Zaključak. uKIM-1 bi mogao biti dodatni pouzdani dijagnostički marker za cRRC na osnovu njegove značajno više preoperativne koncentracije i sniženja vrednosti nakon nefrektomije.

 

Reference

Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63(1): 11−30.

Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet 2009; 373(9669): 1119−32.

Morrissey JJ, London AN, Lambert MC, Kharasch ED. Sensitivity and specificity of urinary neutrophil gelatinase-associated lipo-calin and kidney injury molecule-1 for the diagnosis of renal cell carcinoma. Am J Nephrol 2011; 34(5): 391−8. doi: 10.1159/000330851

Bonventre JV. Kidney Injury Molecule-1 (KIM-1): A specific and sensitive biomarker of kidney injury. Scand J Clin Lab In-vest Suppl 2008; 68(Suppl 241): 78−83.

Han WK, Alinani A, Wu C, Michaelson D, Loda M, McGovern FJ, et al. Human kidney injury molecule-1 is a tissue and urinary tumor marker of renal cell carcinoma. J Am Soc Nephrol 2005; 16(4): 1126−34.

Morrissey JJ, London AN, Luo J, Kharasch ED. Urinary Biomark-ers for the Early Diagnosis of Kidney Cancer. Mayo Clinic Proc 2010; 85(5): 413−21.

Zhang PL, Mashni JW, Sabbisetti VS, Schworer CM, Wilson GD, Wolforth SC, et al. Urine kidney injury molecule-1: a potential non-invasive biomarker for patients with renal cell carcinoma. Int Urol Nephrol 2014; 46(2): 379−88.

Agre P, Nielsen S. The aquaporin family of water channels in kidney. Nephrologie 1996; 17(7): 409−15.

Huang Y, Murakami T, Sano F, Kondo K, Nakaigawa N, Kishida T, et al. Expression of aquaporin 1 in primary renal tumors: a prognostic indicator for clear-cell renal cell carcinoma. Eur Urol 2009; 56(4): 690−8.

Morrissey JJ, Kharasch ED. The Specificity of Urinary Aquapo-rin 1 and Perilipin 2 to Screen for Renal Cell Carcinoma. J Urol 2013; 189(5): 1913−20.

Morrissey JJ, Mobley J, Song J, Vetter J, Luo J, Bhayani S, et al. Urinary Concentrations of Aquaporin-1 and Perilipin-2 in Pa-tients With Renal Cell Carcinoma Correlate With Tumor Size and Stage but not Grade. Urology 2014; 83(1): 256.

Sreedharan S, Petros JA, Master VA, Ogan K, Pattaras JG, Roberts DL, et al. Aquaporin-1 protein levels elevated in fresh urine of renal cell carcinoma patients: potential use for screening and classification of incidental renal lesions. Dis Markers 2014; 2014: 1−6.

Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150(9): 604−12.

Sobin L, Gospodarowicz M, Wittekind C. AJCC staging manual. 7th. Philadelphia: Springer; 2009.

Millet I, Doyon FC, Hoa D, Thuret R, Merigeaud S, Serre I, et al. Characterization of small solid renal lesions: can benign and malignant tumors be differentiated with CT. AJR Am J Roentgenol 2011; 197(4): 887−96.

Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK. Rising Incidence of Small Renal Masses: A Need to Reassess Treat-ment Effect. J Natk Caner Inst 2006; 98(18): 1331−4.

Sahni AV, Ly A, Silverman SG. Usefulness of percutaneous bi-opsy in diagnosing benign renal masses that mimic malignancy. Abdom Imaging 2011; 36(1): 91−101.

Shalabi A, Abassi Z, Awad H, Halachmi S, Moskovitz B, Kluger Y, et al. Urinary NGAL and KIM-1: potential association with histopathologic features in patients with renal cell car-cinoma. World J Urol 2013; 31(6): 1541−5.

Thompson RH, Kurta JM, Kaag M, Tickoo SK, Kundu S, Katz D, et al. Tumor Size is Associated With Malignant Potential in Renal Cell Carcinoma Cases. J Urol 2009; 181(5): 2033−6.

Ku JH, Moon KC, Kwak C, Kim HH. Significance of nuclear grade and tumor size in Korean patients with chromophobe renal cell carcinoma: a comparison with conventional renal cell carcinoma. Urol Oncol 2011; 29(5): 487−91.

Suzuki K, Mizuno R, Mikami S, Tanaka N, Kanao K, Kikuchi E, et al. Prognostic significance of high nuclear grade in patients with pathologic T1a renal cell carcinoma. Jpn J Clin Oncol 2012; 42(9): 831−5.

Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause andcardiovascular mortality in general population cohorts: a collaborativemeta-analysis. Lancet 2010; 375(9731): 2073−81.

Abassi Z, Shalabi A, Sohotnik R, Nativ O, Awad H, Bishara B, et al. Urinary NGAL and KIM-1: biomarkers for assessment of acute ischemic kidney injury following nephron sparing sur-gery. J Urol 2013; 189(4): 1559−66.

Ticozzi-Valerio D, Raimondo F, Pitto M, Rocco F, Bosari S, Perego R, et al. Differential expression of AQP1 in microdomain-enriched membranes of renal cell carcinoma. Proteomics Clin Appl 2007; 1(6): 588−97.

Mazal PR, Stichenwirth M, Koller A, Blach S, Haitel A, Susani M. Expression of aquaporins and PAX-2 compared to CD10 and cytokeratin 7 in renal neoplasms: a tissue microarray study. Mod Pathol 2005; 18(4): 535−40.

Objavljeno
2017/01/24
Broj časopisa
Vol. 73 Br. 3 (2016)
Rubrika
Originalni članak